L-Thyroxine (Levothyroxine), Calcium, and Calcitriol

PART 1: L-THYROXINE (Levothyroxine / T4)

General Principles of Use

• Dose is based on lean body mass: average adult full replacement dose is 1.7 µg/kg/day.
• Goal in primary hypothyroidism: normalize serum TSH.
• Goal in secondary/tertiary hypothyroidism: normalize free T4 (TSH is unreliable as a monitor).
• Dose changes should be followed by TSH measurement at 6 weeks (due to the ~1-week T4 t½ and the time for TSH equilibration).
• In elderly patients and those with cardiac disease or autonomous thyroid function: start low (12.5–50 µg/day) and titrate up by 25 µg/day every 6 weeks.
• Pregnancy: dose requirements increase by ~30% early in the first trimester due to elevated TBG (from estrogen), placental Dio3 activity, and small transplacental T4 passage. The dose should be pre-adjusted as soon as pregnancy is confirmed.
• Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 968

Mechanism of Action

• T3 binds TRs with ~10-fold greater affinity than T4.
• TRs contain a zinc-finger DNA-binding domain and a ligand-binding domain.
• Unliganded TRs bind thyroid hormone response elements (TREs) in gene promoters and repress transcription via corepressor complexes (including histone deacetylases).
• On T3 binding, the corepressor complex is displaced and a coactivator complex is recruited, leading to transcriptional activation of target genes.
• Two TR isoforms: TRα1 (heart rate, body temperature, bone, GI motility) and TRβ1/β2 (liver metabolism/cholesterol; pituitary-hypothalamic TSH feedback; retinal cones, inner ear development).

• Brain development (especially during fetal and neonatal neurogenesis - deficiency causes cretinism)
• Growth (stimulates GH secretion and tissue responsiveness to GH/IGF-1)
• Cardiovascular: increases heart rate and contractility
• Thermogenesis: increases BMR
• Metabolism: facilitates lipolysis, glucose uptake, and cholesterol clearance
• Goodman & Gilman's, pp. 965-966

Indications

1. Hypothyroidism (primary, secondary, tertiary) - the main indication
2. TSH suppression therapy in differentiated thyroid cancer (to reduce TSH-driven tumor growth)
3. Myxedema coma (IV levothyroxine, though some clinicians add IV liothyronine/T3 for faster onset)
4. Subclinical hypothyroidism - evidence for treatment is debated; benefit is clearer in symptomatic patients, those with TSH >10 mIU/L, and in pregnant women
5. Congenital hypothyroidism - early treatment is essential to prevent intellectual impairment
6. Goiter suppression in some cases

Adverse Effects

• Cardiovascular: tachycardia, palpitations, atrial fibrillation (especially in elderly), angina, increased risk of coronary events with over-replacement
• Bone: accelerated bone loss and osteoporosis with prolonged over-treatment (due to increased bone remodeling)
• Neurological: anxiety, insomnia, tremor, irritability, headache
• Weight loss, heat intolerance, sweating
• Myopathy and proximal muscle weakness
• In children: premature closure of epiphyses, behavioral changes

Contraindications

• Untreated adrenal insufficiency (levothyroxine increases cortisol metabolism; initiating thyroid replacement without adequate steroid cover can precipitate adrenal crisis)
• Thyrotoxicosis (any cause)
• Acute MI - use with extreme caution
• Uncorrected hypocortisolism (same principle as adrenal insufficiency)

Drug Interactions

• Goodman & Gilman's, p. 968; Katzung's Basic and Clinical Pharmacology, 16th ed.
• Scott-Brown's Otorhinolaryngology, p. 6914

PART 2: CALCIUM (Supplemental)

General Principles of Use

• PTH: increases serum calcium by stimulating bone resorption, increasing renal tubular calcium reabsorption, and stimulating renal calcitriol synthesis
• Calcitriol (1,25-OH2D3): enhances intestinal calcium absorption and bone calcium mobilization
• Calcitonin: inhibits osteoclast-mediated bone resorption (minor physiological role in adults)

• Calcium carbonate (40% elemental Ca) - cheapest, most widely used; requires gastric acid for absorption (best taken with food)
• Calcium citrate (21% elemental Ca) - absorbed independently of gastric acid; preferred in patients on PPIs, achlorhydria, or bariatric surgery
• Calcium gluconate (9% elemental Ca) - used IV for acute hypocalcemia (more gentle than chloride)
• Calcium chloride (27% elemental Ca) - IV; used in emergencies (cardiac arrest, hyperkalemia, severe hypocalcemia); more irritating to veins
• The Washington Manual of Medical Therapeutics, p. 457

Mechanism of Action / Physiological Role

1. Bone mineralization - hydroxyapatite [Ca10(PO4)6(OH)2] formation
2. Neuromuscular function - intracellular Ca2+ triggers muscle contraction, neurotransmitter release, and action potential propagation
3. Coagulation - Ca2+ is essential for multiple steps in the coagulation cascade (factor X, prothrombin, fibrinogen activation)
4. Intracellular signaling - Ca2+ acts as a second messenger

Indications

1. Hypocalcemia (any cause): hypoparathyroidism, post-thyroidectomy/parathyroidectomy, vitamin D deficiency, CKD, malabsorption syndromes, hypomagnesemia
2. Osteoporosis prevention and treatment (with vitamin D)
3. Dietary supplementation when intake is inadequate (postmenopausal women, elderly, vegetarians, patients on corticosteroids)
4. CKD-mineral bone disease (CKD-MBD): calcium-containing phosphate binders (e.g., calcium carbonate) to control hyperphosphatemia; however, overuse risks vascular calcification
5. Acute management:
   • IV calcium gluconate: tetany, laryngospasm, cardiac arrhythmias from hypocalcemia
   • IV calcium chloride: cardiac arrest (hyperkalemia, calcium channel blocker overdose, hypermagnesemia)
6. Neonatal hypocalcemia in premature infants

Adverse Effects

• Hypercalcemia with excessive dosing: symptoms include polyuria, nephrolithiasis, constipation, anorexia, nausea/vomiting, confusion, shortened QT interval, and at severe levels (>14 mg/dL) - renal failure, arrhythmias, coma ("bones, stones, groans, psychic moans")
• Nephrolithiasis: calcium oxalate or calcium phosphate stones, especially in hypercalciuric individuals
• Constipation: very common with oral calcium carbonate
• Milk-alkali syndrome: hypercalcemia + metabolic alkalosis + renal failure from excessive calcium carbonate ingestion (historical context: overuse of calcium-containing antacids)
• Vascular calcification: concern with prolonged high-dose calcium-based phosphate binders in CKD - contributes to cardiovascular disease
• Cardiovascular risk: some observational data (though debated) suggest excessive supplemental calcium (not dietary) may increase cardiovascular events
• Hypercalciuria: may precede hypercalcemia; increases stone risk
• IV irritation: calcium chloride is highly irritating to veins; extravasation causes tissue necrosis
• Washington Manual, p. 2780-2793; Goodman & Gilman's, block 15

Contraindications

• Hypercalcemia (any cause)
• Hypercalciuria (e.g., sarcoidosis, Williams syndrome, idiopathic hypercalciuria)
• Nephrolithiasis (calcium-containing stones) - relative contraindication; dietary calcium is less harmful than supplements
• Severe renal failure - risk of calcium accumulation and metastatic calcification; careful use only
• Digitalis therapy - hypercalcemia potentiates digoxin toxicity
• Sarcoidosis or other granulomatous diseases - endogenous calcitriol production is unregulated; calcium supplementation can cause severe hypercalcemia

Drug Interactions

PART 3: CALCITRIOL (1,25-Dihydroxyvitamin D3; 1,25-(OH)₂D₃)

General Principles of Use

1. Hepatic 25-hydroxylation: Vitamin D3 (cholecalciferol, from skin synthesis or diet) → 25-hydroxyvitamin D3 (25-OHD3, calcidiol) - the principal circulating storage form
2. Renal 1α-hydroxylation (by CYP27B1, stimulated by PTH, hypocalcemia, hypophosphatemia, and inhibited by FGF23 and hyperphosphatemia): 25-OHD3 → 1,25-(OH)₂D3 (calcitriol)

• Goodman & Gilman's, block 15, p. 1072; Washington Manual

Mechanism of Action

1. Intestinal calcium absorption (main mechanism): Calcitriol upregulates epithelial calcium channel TRPV6, the intracellular calcium transporter calbindin-D, and the basolateral Ca2+/ATPase pump (PMCA1b) - the transcellular calcium absorption pathway that dominates when dietary calcium is deficient
2. Renal calcium and phosphate handling: Enhances tubular calcium reabsorption (synergizes with PTH); promotes phosphaturia (FGF23-like effect at high concentrations)
3. Bone: In concert with PTH, calcitriol stimulates osteoblasts to produce RANKL, which drives osteoclast differentiation and bone resorption to mobilize calcium into the ECF. It also supports osteoblast differentiation and bone mineralization
4. Parathyroid gland: Directly suppresses PTH gene transcription via VDR (negative feedback)
5. Immune and other tissues: VDR is expressed in immune cells, skin, muscle, and many other tissues - calcitriol has immunomodulatory effects and promotes keratinocyte differentiation (basis for topical use in psoriasis)
6. FGF23 regulation: High serum 1,25-OH2D3 stimulates FGF23 secretion from osteocytes, which then suppresses further calcitriol synthesis (feedback loop)

• Goodman & Gilman's, block 15, p. 1072

Indications

1. Hypoparathyroidism - in the absence of PTH, calcitriol + calcium is the only mechanism to normalize serum calcium via intestinal absorption
2. CKD-mineral bone disease (CKD-MBD) / Renal osteodystrophy - the kidneys cannot synthesize calcitriol, leading to secondary hyperparathyroidism; calcitriol or its analogs (paricalcitol, doxercalciferol) suppress PTH and treat metabolic bone disease
3. Nutritional rickets (severe cases unresponsive to standard vitamin D)
4. Vitamin D-dependent rickets type 1 (hereditary deficiency of 1α-hydroxylase) - calcitriol bypasses the defective enzyme
5. Osteomalacia due to liver disease or malabsorption (when 25-hydroxylation capacity is impaired)
6. Osteoporosis - often combined with calcium; evidence strongest for reducing fall-related fractures in elderly (vitamin D effect on muscle)
7. Psoriasis - topical calcitriol (and analogs like calcipotriol) inhibit keratinocyte proliferation and promote differentiation
8. Hypophosphatemic rickets (with phosphate supplementation)

Adverse Effects

• Nephrocalcinosis and nephrolithiasis
• Polyuria, polydipsia (nephrogenic diabetes insipidus from calcium effects on renal tubules)
• Anorexia, nausea, vomiting, constipation
• Metastatic calcification (soft tissues, blood vessels, corneas, kidneys)
• Hypertension
• Confusion, lethargy, coma in severe cases
• Shortened QT interval; cardiac arrhythmias
• Milk-alkali syndrome if combined with excess calcium supplementation

• Goodman & Gilman's, block 15

Contraindications

• Hypercalcemia (any cause)
• Vitamin D toxicity
• Hypercalciuria (e.g., calcium kidney stones)
• Malabsorption not requiring calcitriol (use only when intestinal pathway can be used)
• Sarcoidosis and other granulomatous diseases: these macrophages express 1α-hydroxylase unregulated by PTH or calcium, generating excess calcitriol autonomously; exogenous supplementation can cause dangerous hypercalcemia
• Severe hyperphosphatemia in CKD (calcitriol may worsen calcium-phosphate product and worsen vascular calcification; phosphate must be controlled first)

Drug Interactions

Summary Table